Diagnostic Collaboration and Licensing Deals 2020-2025
상품코드:1727697
리서치사:Current Partnering, a brand of Biopharma Research Ltd.
발행일:2025년 05월
페이지 정보:영문 700+ Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 바이오의약품 산업에 대해 조사 분석했으며, 2020-2025년 진단 분야의 공동 연구 및 라이선스 계약 1,449건에 대해 계약 조건 등 상세한 데이터를 정리하여 전해드립니다.
목차
주요 요약
제1장 소개
제2장 진단 계약 동향
소개
지난 몇 년간 진단 계약
가장 활발한 진단 교섭자
진단 계약 : 계약 유형별
진단 계약 : 치료 분야별
진단 계약 : 산업 부문별
진단 계약의 계약 조건
진단 계약 헤드라인 금액
진단 계약 선급금
진단 계약 단계별 기술료
진단 로열티율
제3장 주요 진단 계약
소개
상위 진단 계약(금액)
제4장 가장 활발한 진단 교섭자
소개
가장 활발한 진단 교섭자
가장 활발한 진단 계약 기업 개요
제5장 진단 계약 디렉토리
소개
진단 계약 디렉토리
제6장 진단적 계약 : 기술 유형별
계약 디렉토리
계약 디렉토리 - 진단 계약 : 기업별(A-Z)
계약 디렉토리 - 진단 계약 : 계약 유형별
계약 디렉토리 - 진단 계약 : 치료 분야별
계약 유형의 정의
Biopharma Research Ltd에 대해
Current Partnering
Current Agreements
Current Partnering의 최근 보고서 제목
ksm
영문 목차
영문목차
Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of diagnostic deals from 2020 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 1449 diagnostic deals announced since 2020 including financial terms where available including links to online deal records of actual diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in diagnostic dealmaking since 2020.
Chapter 3 provides an overview of the leading diagnostic deals since 2020. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in diagnostic dealmaking with a brief summary followed by a comprehensive listing of diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of diagnostic deals signed and announced since Jan 2020, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of diagnostic partnering deals signed and announced since Jan 2020. The chapter is organized by specific diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in diagnostic deal making since 2020.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2020
Browse diagnostic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
Diagnostic Collaboration and Licensing Deals includes:
Trends in diagnostic dealmaking in the biopharma industry
Directory of diagnostic deal records covering pharmaceutical and biotechnology
The leading diagnostic deals by value
Most active diagnostic licensing dealmakers
Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in diagnostic dealmaking
2.1. Introduction
2.2. Diagnostic deals over the years
2.3. Most active diagnostic dealmakers
2.4. Diagnostic deals by deal type
2.5. Diagnostic deals by therapy area
2.6. Diagnostic deals by industry sector
2.7. Deal terms for diagnostic deals
2.7.1 Diagnostic deals headline values
2.7.2 Diagnostic deal upfront payments
2.7.3 Diagnostic deal milestone payments
2.7.4 Diagnostic royalty rates
Chapter 3 - Leading diagnostic deals
3.1. Introduction
3.2. Top diagnostic deals by value
Chapter 4 - Most active diagnostic dealmakers
4.1. Introduction
4.2. Most active diagnostic dealmakers
4.3. Most active diagnostic deals company profiles
